



Panton-Valentine Leukocidin–Secreting Staphylococcus aureus Pneumonia Complicating COVID-19

Claire Duployez, Rémi Le Guern, Claire Tinez, Anne-Laure Lejeune, Laurent Robriquet, Sophie Six, Caroline Loiez, Frédéric Wallet

► To cite this version:

Claire Duployez, Rémi Le Guern, Claire Tinez, Anne-Laure Lejeune, Laurent Robriquet, et al.. Panton-Valentine Leukocidin–Secreting Staphylococcus aureus Pneumonia Complicating COVID-19. Emerging Infectious Diseases, 2020, 26 (8), pp.1939-1941. 10.3201/eid2608.201413 . hal-02566167

HAL Id: hal-02566167

<https://hal.science/hal-02566167>

Submitted on 12 Nov 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1 **Running Title :** PVL-secreting *S. aureus* and SARS-CoV-2 coinfection

2 **Keywords :** COVID-19 ; necrotizing pneumonia; Panton-Valentine leukocidin; SARS-CoV-

3 2; *Staphylococcus aureus*

4 **Title:** Panton-Valentine leukocidin-secreting *Staphylococcus aureus* complicating SARS-

5 CoV-2 infection : a case report

6 **Authors:** Claire Duployez, Rémi Le Guern, Claire Tinez, Anne-Laure Lejeune, Laurent

7 Robriquet, Sophie Six, Caroline Loïez, Frédéric Wallet

8 **Author afiliations:**

9 CHU Lille, F-59000 Lille, France (C. Duployez, R. Le Guern, C. Tinez, AL. Lejeune, L.

10 Robriquet, S. Six, C. Loïez, F. Wallet)

11 Univ. Lille, F-59000 Lille, France (C. Duployez, R. Le Guern, AL. Lejeune)

12

13 **Abstract – 42 words**

14 Necrotizing pneumonia induced by Panton-Valentine leukocidin (PVL) secreting
15 *Staphylococcus aureus* is a rare but life-threatening infection. It has been described following
16 influenza. We present a fatal case of this superinfection in a young adult infected by Severe
17 Acute Respiratory Syndrome Coronavirus 2.

18

19 **Text – 678 words**

20 Panton-Valentine leukocidin (PVL) is a cytotoxin produced by some strains of
21 *Staphylococcus aureus*. These strains are responsible for primary skin infections and
22 necrotizing pneumonia. This rare entity is mainly described in young immunocompetent
23 patients with an influenza-like prodrome and has a high lethality rate (1, 2). We report herein
24 a case of necrotizing pneumonia induced by PVL-secreting methicillin-susceptible *S. aureus*
25 in a patient infected by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).

26 In March 2020, during SARS-CoV-2 outbreak in France, a man in his thirties without
27 comorbidities presented at the emergency department with fever, cough, and blood-streaked
28 sputum developing for 3 days. A diagnosis of pleuropneumonia was made and antimicrobial
29 therapy was initiated with cefotaxime plus metronidazole. *Streptococcus pneumoniae* and
30 *Legionella pneumophila* serotype 1 urinary antigens were negative; respiratory viruses
31 screening PCR was negative. The next day, further respiratory deterioration required his
32 transfer in Intensive Care Unit (ICU) for intubation, mechanical ventilation, and inotropic
33 support. Spiramycin was added to the previous probabilistic antibiotic. Chest CT pointed out a
34 parenchymal consolidation of the left upper lung, without ground-glass opacities commonly
35 described in Coronavirus Disease 2019 (COVID-19) (3). Four days after intubation, the
36 patient was not getting better. SARS-CoV-2 RT-PCR was performed on endotracheal
37 aspirate, using the method developed by the National Reference Centre for respiratory viruses

38 (Institut Pasteur, Paris), and was positive for the pandemic SARS-CoV-2 (4). Another chest
39 CT showed worsening of bilateral parenchymal damage with complete consolidation of the
40 left lung, cavitary lesions suggestive of multiple abscesses, and appearance of areas of
41 ground-glass opacities in the right lung (Figure 1). The chest radiograph also revealed a left
42 pleural effusion. The bacteriological analysis of pleural drainage revealed the presence of
43 Gram-positive cocci; the culture yielded a monomicrobial *S. aureus*, identified using MALDI-
44 TOF spectrometry mass (Bruker Daltonics, Wissembourg, France). The strain was resistant
45 only to penicillin G (VITEK 2 system, BioMérieux, Marcy l'Etoile, France). Because of this
46 necrotizing pneumonia associated with acute respiratory distress syndrome, a PVL-producing
47 strain was suspected. PVL production was confirmed using a specific PCR, as described
48 previously by Deurenberg et al. (5). Previous antimicrobial therapy was changed into
49 oxacillin plus clindamycin (for antitoxin effect) against methicillin-susceptible *S. aureus*, and
50 lopinavir/ritonavir (quickly stopped for suspected toxicity) plus azithromycin against SARS-
51 CoV-2. Three days later, given a lack of clinical improvement, antimicrobial therapy was
52 incremented for piperacillin-tazobactam plus linezolid (for antitoxin effect). At the
53 bronchoscopy, the left bronchial tree was obstructed by purulent secretions. Owing to
54 deterioration of respiratory, renal and liver functions, venovenous extracorporeal membrane
55 oxygenation (ECMO) and anticoagulation were initiated ten days after ICU admission. Two
56 days later, upper left lobectomy was performed, and antimicrobial therapy was incremented
57 with meropenem, gentamicin plus linezolid. Unfortunately, the patient finally died 17 days
58 after his admission to the hospital.

59 PVL-secreting *S. aureus* necrotizing pneumonia is frequently preceded by an
60 influenza-like infection (6), which may be a possible causative factor. Particularly, influenza
61 virus is known to impede phagocytic killing and damage the bronchial epithelium, thus
62 reducing secretin clearance and facilitating bacteria adhesion (2). It also induces an influx of

63 immune cells to lung tissues, including neutrophils; the rapid killing of these cells by PVL
64 and release of the inflammatory mediators may promote disease development by damaging
65 the epithelium (7, 8). The association of PVL-secreting *S. aureus* and influenza virus has been
66 previously reported in the literature (6, 9). We report a PVL-secreting *S. aureus*
67 superinfection in COVID-19. It points out that the new SARS-CoV-2 is, in the same way, a
68 facilitating factor for PVL-producing *S. aureus* necrotizing pneumonia.

69 In 2003, during SARS-CoV outbreak, an increase in *S. aureus* superinfection (mostly
70 methicillin-resistant *S. aureus* ventilator-acquired pneumonia) was described. Given common
71 points between SARS-CoV-2 and previous coronaviruses, Lupia et al. discussed this issue for
72 COVID-19, suggesting to consider anti-methicillin-resistant *S. aureus* coverage in order to
73 reduce the risk of superinfection (10).

74 In PVL-producing *S. aureus* superinfection, prescribing antibiotics that have an antitoxin
75 effect, such as clindamycin or linezolid, remains important (2). Thus, in previously healthy
76 young adults admitted in ICU for COVID-19 with *S. aureus* superinfection, a PVL-producing
77 strain should be evocated.

78

79 **References**

- 80 1. Gillet Y, Issartel B, Vanhems P, Fournet JC, Lina G, Bes M, et al. Association
81 between *Staphylococcus aureus* strains carrying gene for Panton-Valentine leukocidin
82 and highly lethal necrotizing pneumonia in young immunocompetent patients. Lancet.
83 2002;359:753-9.
- 84
- 85 2. Kreienbuehl L, Charbonney E, Eggimann P. Community-acquired necrotizing
86 pneumonia due to methicillin-sensitive *Staphylococcus aureus* secreting Panton-

- 87 Valentine leukocidin: a review of case reports. Ann Intensive Care. 2011; 1: 52.
88 doi: 10.1186/2110-5820-1-52
- 89
- 90 3. Kooraki S, Hosseiny M, Myers L, Gholamrezanezhad A. Coronavirus (COVID-19)
91 Outbreak: What the Department of Radiology Should Know. J Am Coll Radiol. 2020
92 Feb 19. pii: S1546-1440(20)30150-2. doi: 10.1016/j.jacr.2020.02.008.
- 93
- 94 4. Bernard Stoecklin S, Rolland P, Silue Y, Mailles A, Campese C, Simondon A, et al.
95 First cases of coronavirus disease 2019 (COVID-19) in France: surveillance,
96 investigations and control measures, January 2020. Euro Surveill. 2020 Feb;25(6). doi:
97 10.2807/1560-7917.ES.2020.25.6.2000094.
- 98
- 99 5. Deurenberg RH, Vink C, Driessen C, Bes M, London N, Etienne J, et al. Rapid
100 detection of Panton-Valentine leukocidin from clinical isolates of *Staphylococcus*
101 *aureus* strains by real-time PCR. FEMS Microbiol Lett. 2004 Nov 15;240(2):225-8.
102 doi: 10.1016/j.femsle.2004.09.031.
- 103
- 104 6. Jacquot A, Luyt CE, Kimmoun A, Levy B, Baux E; Fluvalentine Study group.
105 Epidemiology of post-influenza bacterial pneumonia due to Panton-Valentine
106 leucocidin positive *Staphylococcus aureus* in intensive care units: a retrospective
107 nationwide study. Intensive Care Med. 2019;45(9):1312–1314. doi:10.1007/s00134-
108 019-05665-3
- 109
- 110 7. Niemann S, Ehrhardt C, Medina E, Warnking K, Tuchscherer L, Heitmann V et al.
111 Combined action of influenza virus and *Staphylococcus aureus* panton-valentine

- 112 leukocidin provokes severe lung epithelium damage. J Infect Dis. 2012;206(7):1138–
113 1148. doi:10.1093/infdis/jis468
- 114
- 115 8. Löffler B, Niemann S, Ehrhardt C, Horn D, Lanckohr C, Lina G et al. Pathogenesis of
116 *Staphylococcus aureus* necrotizing pneumonia: the role of PVL and an influenza
117 coinfection. Expert Rev Anti Infect Ther. 2013;11(10):1041–1051.
118 doi:10.1586/14787210.2013.827891
- 119
- 120 9. Riedweg-Moreno K, Wallet F, Blazejewski C, Goffard A. Successful management of
121 Panton-Valentine leukocidine-positive necrotising pneumonia and A/H1N12009
122 influenzavirus coinfection in adult. BMJ Case Rep. 2014;2014:bcr2013201120.
123 doi:10.1136/bcr-2013-201120
- 124
- 125 10. Lupia T, Scabini S, Mornese Pinna S, Di Perri G, De Rosa FG, Corcione S. 2019
126 novel coronavirus (2019-nCoV) outbreak: A new challenge. 2020 Mar. J Glob
127 Antimicrob Resist. 2020;21:22–27. doi:10.1016/j.jgar.2020.02.021.
- 128
- 129 Address for correspondence : Claire Duployez, Laboratoire de Bactériologie - Institut de
130 Microbiologie, Centre de Biologie Pathologie, F-59037 – Lille CEDEX, France ; email :
131 claire.duployez@chru-lille.fr; Telephone number: +33 3.20.44.54.80 ; Fax number: +33
132 3.20.44.48.95